- Home
- CHRS vs SCPH Comparison
CHRS vs SCPH Comparison
Compare CHRS & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SCPH
- Stock Information
- Founded
- CHRS 2010
- SCPH 2013
- Country
- CHRS United States
- SCPH United States
- Employees
- CHRS N/A
- SCPH N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- SCPH Health Care
- Exchange
- CHRS Nasdaq
- SCPH Nasdaq
- Market Cap
- CHRS 159.2M
- SCPH 299.0M
- IPO Year
- CHRS 2014
- SCPH 2017
- Fundamental
- Price
- CHRS $1.53
- SCPH $5.62
- Analyst Decision
- CHRS Strong Buy
- SCPH Buy
- Analyst Count
- CHRS 4
- SCPH 3
- Target Price
- CHRS $4.51
- SCPH $12.00
- AVG Volume (30 Days)
- CHRS 1.3M
- SCPH 2.5M
- Earning Date
- CHRS 11-05-2025
- SCPH 11-12-2025
- Dividend Yield
- CHRS N/A
- SCPH N/A
- EPS Growth
- CHRS N/A
- SCPH N/A
- EPS
- CHRS 1.55
- SCPH N/A
- Revenue
- CHRS $272,209,000.00
- SCPH $49,969,000.00
- Revenue This Year
- CHRS N/A
- SCPH $104.30
- Revenue Next Year
- CHRS $109.48
- SCPH $76.06
- P/E Ratio
- CHRS $0.98
- SCPH N/A
- Revenue Growth
- CHRS 52.33
- SCPH 107.79
- 52 Week Low
- CHRS $0.66
- SCPH $1.94
- 52 Week High
- CHRS $2.43
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- CHRS 74.22
- SCPH 63.32
- Support Level
- CHRS $1.23
- SCPH $4.33
- Resistance Level
- CHRS $1.40
- SCPH $5.62
- Average True Range (ATR)
- CHRS 0.09
- SCPH 0.04
- MACD
- CHRS 0.01
- SCPH -0.01
- Stochastic Oscillator
- CHRS 97.56
- SCPH 80.00
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.